It’s only fair to share… RADOTINIB Molecular FormulaC27H21F3N8O Average mass530.504 Da 4-Methyl-N-[3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)phenyl]-3-{[4-(2-pyrazinyl)-2-pyrimidinyl]amino}benzamide 4-methyl-N-[3-(4-methylimidazole-l-yl)-5-trifluoromethyl-phenyl] – 3-(4-pyrazine-2-yl-pyrimidine-2-yl amino)benzamide 9242 926037-48-1 [RN] 926037-48-1 (Radotinib); 926037-85-6 (Radotinib 2HCl); Benzamide, 4-methyl-N-[3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)phenyl]-3-[[4-(2-pyrazinyl)-2-pyrimidinyl]amino]- I284LJY110, IY5511 UNII-I284LJY110 радотиниб رادوتينيب 雷度替尼 MOA：Bcr-Abl tyrosine kinase inhibitor Indication：Chronic myeloid leukemia (CML ) Company：IL-Yang (Originator) IY-5511; IY-5511A3001 Approval Date Approval Type Trade Name Indication Dosage Form Strength Company Review Classification …
Tag «Chronic Myeloid Leukemia»
ABL 001, Asciminib
It’s only fair to share… ABL001 / Asciminib Cas 1492952-76-7 Chemical Formula: C20H18ClF2N5O3 Molecular Weight: 449.8428 Elemental Analysis: C, 53.40; H, 4.03; Cl, 7.88; F, 8.45; N, 15.57; O, 10.67 N-[4-[Chloro(difluoro)methoxy]phenyl]-6-[(3R)-3-hydroxypyrrolidin-1-yl]-5-(1H-pyrazol-5-yl)pyridine-3-carboxamide 3-Pyridinecarboxamide, N-[4-(chlorodifluoromethoxy)phenyl]-6-[(3R)-3-hydroxy-1-pyrrolidinyl]-5-(1H-pyrazol-3-yl)- PHASE 3, Chronic Myeloid Leukemia, NOVARTIS Asciminib is an orally bioavailable, allosteric Bcr-Abl tyrosine kinase inhibitor with potential antineoplastic activity. Designed to overcome resistance, ABL001 binds …